These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study. Horinouchi H; Nogami N; Saka H; Nishio M; Tokito T; Takahashi T; Kasahara K; Hattori Y; Ichihara E; Adachi N; Noguchi K; Souza F; Kurata T Cancer Sci; 2021 Aug; 112(8):3255-3265. PubMed ID: 34036692 [TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994 [TBL] [Abstract][Full Text] [Related]
29. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study. Wu YL; Zhang L; Fan Y; Zhou J; Zhang L; Zhou Q; Li W; Hu C; Chen G; Zhang X; Zhou C; Dang T; Sadowski S; Kush DA; Zhou Y; Li B; Mok T Int J Cancer; 2021 May; 148(9):2313-2320. PubMed ID: 33231285 [TBL] [Abstract][Full Text] [Related]
30. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. Powell SF; Rodríguez-Abreu D; Langer CJ; Tafreshi A; Paz-Ares L; Kopp HG; Rodríguez-Cid J; Kowalski DM; Cheng Y; Kurata T; Awad MM; Lin J; Zhao B; Pietanza MC; Piperdi B; Garassino MC J Thorac Oncol; 2021 Nov; 16(11):1883-1892. PubMed ID: 34265431 [TBL] [Abstract][Full Text] [Related]
31. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. Cortes J; Rugo HS; Cescon DW; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Perez-Garcia J; Iwata H; Masuda N; Torregroza Otero M; Gokmen E; Loi S; Guo Z; Zhou X; Karantza V; Pan W; Schmid P; N Engl J Med; 2022 Jul; 387(3):217-226. PubMed ID: 35857659 [TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559 [TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC; N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856 [TBL] [Abstract][Full Text] [Related]
34. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ; Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370 [TBL] [Abstract][Full Text] [Related]
35. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354 [TBL] [Abstract][Full Text] [Related]
37. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969 [TBL] [Abstract][Full Text] [Related]
38. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497 [TBL] [Abstract][Full Text] [Related]
39. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Long GV; Dummer R; Hamid O; Gajewski TF; Caglevic C; Dalle S; Arance A; Carlino MS; Grob JJ; Kim TM; Demidov L; Robert C; Larkin J; Anderson JR; Maleski J; Jones M; Diede SJ; Mitchell TC Lancet Oncol; 2019 Aug; 20(8):1083-1097. PubMed ID: 31221619 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Balar AV; Castellano DE; Grivas P; Vaughn DJ; Powles T; Vuky J; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Necchi A; Petrylak DP; Plimack ER; Xu JZ; Imai K; Moreno BH; Bellmunt J; de Wit R; O'Donnell PH Ann Oncol; 2023 Mar; 34(3):289-299. PubMed ID: 36494006 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]